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Hidden genomic MHC disparity 
between HLA-matched sibling 
pairs in hematopoietic stem cell 
transplantation
Satu Koskela  1, Jarmo Ritari1, Kati Hyvärinen1, Tony Kwan  2, Riitta Niittyvuopio3,  
Maija Itälä-Remes3, Tomi Pastinen2 & Jukka Partanen1
Matching classical HLA alleles between donor and recipient is an important factor in avoiding adverse 
immunological effects in HSCT. Siblings with no differences in HLA alleles, either due to identical-
by-state or identical-by-descent status, are considered to be optimal donors. We carried out a 
retrospective genomic sequence and SNP analysis of 336 fully HLA-A, -B, -DRB1 matched and 14 
partially HLA-matched sibling HSCT pairs to determine the level of undetected mismatching within the 
MHC segment as well as to map their recombination sites. The genomic sequence of 34 genes locating 
in the MHC region revealed allelic mismatching at 1 to 8 additional genes in partially HLA-matched 
pairs. Also, fully matched pairs were found to have mismatching either at HLA-DPB1 or at non-HLA 
region within the MHC segment. Altogether, 3.9% of fully HLA-matched HSCT pairs had large genomic 
mismatching in the MHC segment. Recombination sites mapped to certain restricted locations. The 
number of mismatched nucleotides correlated with the risk of GvHD supporting the central role of full 
HLA matching in HSCT. High-density genome analysis revealed that fully HLA-matched siblings may 
not have identical MHC segments and even single allelic mismatching at any classical HLA gene often 
implies larger genomic differences along MHC.
Matching human leukocyte antigen (HLA) alleles between the donor and recipient of hematopoietic stem cell 
transplantation (HSCT) is crucial to reduce the risk of graft-versus-host disease (GvHD), a major life-threatening 
complication of HSCT. The donor search usually begins by HLA genotyping of immediate family members to find 
an HLA-identical sibling that is considered to be an optimal donor in the HSCT setting. Due to the low rate of 
intra-major histocompatibility complex (MHC) recombination, a patient and a sibling donor have a 25% chance 
to be HLA identical, i.e., they share the same two HLA haplotypes.
The segregation of all four parental HLA haplotypes in a family can often be defined on basis of HLA-A, 
-B, -DRB1 typing when either parents or sufficient number of siblings are available. As there is a strong linkage 
disequilibrium (LD) between HLA-B and -C genes and HLA-DRB1 and -DQB1 genes1, respectively, HLA-A,-B 
and -DRB1 matching usually implies also HLA-C and -DQB1 matching. However, due to the limited number of 
siblings and ever-older HSCT patients, all four haplotypes are not always distinguished in a family. Many HLA 
matched siblings can therefore be classified merely as HLA identical-by-state, rather than identical-by-descent. A 
chance for selecting only HLA matched but not HLA identical donor increases especially when similar haplotypes 
with the same HLA alleles in different combinations segregate in a family. To overcome these problems some 
histocompatibility laboratories now type larger than the minimal set of HLA genes.
In the absence of an HLA identical sibling donor, i.e. 6/6 HLA-matched donor, HLA-mismatched related 
donor with a single mismatch at HLA-A, -B or -DRB1 is an option and requires typing of at least one addi-
tional classical HLA gene, HLA-C or -DQB1 or -DPB1. However, these 5/6 HLA-matched sibling pairs may have 
allelic disparities at other classical HLA genes and/or elsewhere in the major histocompatibility complex (MHC). 
There is emerging evidence that the role of the MHC in GvHD susceptibility may be more complex than merely 
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matching the alleles of the classical HLA genes. Some HLA-related or non-HLA variations within the MHC may 
be associated with GvHD risk2–7.
The major histocompatibility complex encompasses 4 Mbp of the short arm of chromosome 6p21.3. In addi-
tion to the classical HLA genes, non-classical HLA genes and a number of other genes, some with immunological 
functions, are found in this segment. A hallmark of the MHC is strong LD8,9. In many populations, a num-
ber of conserved extended or ancestral MHC haplotypes with a strong LD are present at a high frequency10–13. 
According to Baschal et al.14, conservation in a haplotype group varies greatly, but one-quarter of haplotype 
groups have greater than 50% conservation from HLA-DRB1 to HLA-A segment. For example, the common 
European HLA-A1-B8-DR3 haplotype is highly congruent, with 92% of chromosomes having 99.8% allelic 
identity.
Despite of the strong LD, a few recombination hot spots are located within the MHC region15,16. For example, 
a dense cluster of recombination hot spots maps to a segment between HLA-DQB1 and HLA-DPB1 genes in 
the MHC class II, resulting in a high recombination rate between these genes. In contrast, the segment between 
HLA-DRB1 and HLA-DQB1 genes, which has a similar physical length, has a very low recombination rate13,17,18. 
Active recombination sites have also been observed telomeric to HLA-A gene in the MHC class I and between 
HLA-B and HLA-DRB1 genes in the MHC class III region19,20. The locations of recombination hot spots have 
been found to be the same across populations, although some appear to be haplotype or population specific. 
These recombination sites lead to segmented blocks in the MHC.
Very few studies have used systematic genomic approaches to estimate the level of the MHC identity in 
HLA-matched sibling HSCTs21. The present genomic study can help us to assess whether current HLA matching 
protocols, in particular the set of HLA genes genotyped, are sufficient and how much there is hidden mismatching 
in the non-HLA MHC region. Furthermore, we can estimate the level of intra-MHC recombination and their 
boundaries. To address the question of genomic MHC identity in the HLA and non-HLA gene regions, we per-
formed a retrospective analysis of 5137 single nucleotide polymorphisms (SNPs) located in the MHC segment in 
261 HLA-matched sibling allogeneic HSCTs. A more detailed comparison utilizing the full genomic sequence of 
the MHC was performed in another set of 89 potential sibling HSCT pairs. The high-density SNP data together 
with the full MHC sequence analysis created an opportunity to uncover hidden mismatches within the MHC 
segment in apparently HLA-matched sibling HSCTs.
Results
Study cohort 1. Altogether, 261 pairs with a patient and his/her HLA typed sibling were included in the 
study. No parents were available for clinical HLA typing. Therefore, in most cases only HLA identical-by-state 
status, rather than identical-by-descent status, could be assigned for the HSCT patient-donor pairs.
HLA match status and imputation. Based on the clinical HLA typing of five classical HLA genes a total 
of 255 of 261 pairs were 6/6 HLA-matched (HLA-A, -B, -DRB1). Six pairs were known to be 5/6 HLA-matched 
prior to the present study. Antigen mismatching occurred at HLA-A in three pairs, at HLA-B in two pairs and at 
HLA-DRB1 in one pair. One of the two pairs with mismatching at HLA-B had mismatching also at HLA-C and 
the pair with an antigen mismatch at HLA-DRB1 was mismatched also at HLA-DQB1 (Table 1).
To estimate the level of identity-by-state in seven classical HLA genes HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 
and -DPB1 in each 261 HSCT pair, we used an Immunochip array to screen SNP mismatches within the MHC. 
We explored the actual HLA match status of the six 5/6 HLA-matched HSCT pairs by imputing HLA alleles to the 
resolution level of unique amino acid chains (four-digit resolution).
Imputed four-digit HLA alleles were in 100% concordance with two-digit clinical HLA types. The number of 
imputed alleles varied between 48 and 1646 depending on the specific locus. Absolute posterior probability Q2 for 
HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 varied between 0.54–1.00, 0.19–1.00, 0.17–1.00, 0.19–1.00, 
0.35–1.00, 0.46–1.00 and 0.12–1.00, respectively. The differences of Q2 values within HLA-mismatched pairs 
were relatively low: 0.00–0.01 for HLA-A, 0.00–0.28 for HLA-B, 0.17 for HLA-C, 0.07 for HLA-DRB1, 0.44 for 
HLA-DQA1, 0.01 for HLA-DQB1 and 0.01–0.46 for HLA-DPB1. Metrics of the imputation and imputed HLA 
alleles for each pair are described in more detail in Supplementary Table S1.
Imputation revealed additional mismatching at those classical HLA genes not typed prior to transplantation: 
pair 2329, which was known to have allelic mismatches at HLA-DRB1 and -DQB1, was also mismatched at 
HLA-DQA1, and four pairs with allelic mismatching at HLA-A or -B were also mismatched at HLA-DPB1 (pairs 
2329, 3205, 4426 and 5366 in Table 1 and Supplementary Table S2). Furthermore, mismatching at HLA-DPB1 
was revealed in four out of 255 fully (6/6) HLA-matched pairs (pairs 1812, 3450, 4152 and 5236 in Table 1). 
Subsequent HLA typing by the reference technique SSO confirmed allelic mismatching at HLA-DPB1 in all the 
pairs from which DNA was available, that is, five out of eight DPB1-mismatched pairs. In total, 10 of the 261 
(3.8%) HSCTs in study cohort 1 were performed between pairs with at least one allelic mismatch in the classical 
HLA genes.
MHC segment identity. We next scrutinized the level of overall SNP matching within the entire MHC 
region in each of the 261 HSCT pairs based on the matching of the 5137 SNPs that had been mapped to that 
segment. Figure 1a shows the matched (dark green) and mismatched (yellow) SNPs in HSCT pairs with large 
mismatching fragments. The mismatched fragments covered those HLA genes that were known to have allelic 
mismatches by clinical HLA typing or HLA imputation. Thus, the 10 HSCT pairs with identified mismatching at 
the classical HLA had mismatched SNP clusters especially at the particular gene with an allele mismatch. The mis-
matched regions, however, covered larger areas than only the exact HLA gene with allelic mismatching. For exam-
ple, pair 2329, which was originally known to be mismatched at HLA-DRB1 and -DQB1 alleles, showed SNP 
mismatches encompassing the entire segment from complement C4 gene to the telomeric side of HLA-DPB1. In 
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two HLA-B allele mismatched pairs (pairs 4754 and 5366 in Fig. 1a), SNP mismatching extended close to comple-
ment C4 gene at the centromeric side of HLA-B and close to HLA-E at the telomeric side. Pair 4754 additionally 
had SNP mismatching telomeric to HLA-A gene. In all three pairs with mismatched HLA-A alleles (pairs 3205, 
4426, 4658) SNP mismatched areas were large extending far from HLA-A gene in both directions. Mismatching 
at HLA-DPB1 reached far to the centromeric side of the gene in six mismatched pairs (3205, 5366, 1812, 2934, 
5236, 4706). The number of mismatched SNPs and putative boundaries of the recombination segments are listed 
in Supplementary Table S3.
In addition to the 10 mismatched pairs described above, four other HSCT pairs had clusters of mismatched 
SNPs within the MHC. In other words, they were found to be not identical-by-state. These SNP mismatches were 
located telomeric to HLA-A or centromeric to HLA-DPB1 (pairs 2934, 3446, 4706, 3803 in Fig. 1a) covering the 
genomic area where non-classical HLA genes or HLA pseudogenes reside: HLA-G and -F genes at the telomeric 
end of the MHC and HLA-DPB2 at the other end. Surprisingly, pair 4205, which had no HLA allele disparities 
in the seven classical HLA genes (14/14 match), was found to have clusters of mismatched SNPs in the MHC. 
Large regions telomeric to HLA-A, between HLA-A and HLA-C and between HLA-B and DRB1, encompassing 
the entire TNF-C4 fragment in the MHC class III, were covered with SNP mismatches. Taken those mismatches 
in the MHC region into account that were not known before the transplantation, altogether 3.5% (9/255) of the 
HSCT pairs in study cohort 1 were mismatched.
The remaining 246 fully 6/6 HLA-matched HSCT sibling pairs had no known HLA allelic mismatches or SNP 
mismatches, barring some apparently sporadic single SNP differences (Supplementary Fig. S1).
Study cohort 2. Study cohort 2 consisted of 89 HLA-matched sibling HSCT pairs, of which five were known 
to have a single allelic HLA-A mismatch and three to have HLA-B and -C mismatch. None of them had mis-
matching at HLA-DRB1 (Table 2).
HLA match status. The full genomic MHC segment (4.5 Mbp) was sequenced from all 89 HSCT pairs. 
Alleles of the classical HLA genes HLA-A, -C, -B, -DRB1, -DQA1, -DQB1, and -DPB1 were assigned based on the 
genomic sequence using Omixon Explore 1.2.0 at four-digit and six-digit resolution levels (missense and silent 
mutations). There was 100% concordance to the clinical HLA-A, -C, -B, -DRB1, -DQB1 typing. As in cohort 
1, additional disparities at HLA-DPB1 were found in two 5/6 HLA-matched HSCT pairs (pairs 5426, 5782 in 
Table 2). No allelic disparities were found at HLA-DRB1 or -DQA1.
Furthermore, the alleles of 27 additional genes in the MHC region were assigned in pairs with known HLA 
mismatching. These genes included non-classical HLA genes, HLA pseudogenes and non-HLA genes: HLA-F, 
-V, -G, -H, -K, -J, -L, -E, -DRA, -DRB2-9, -DOB, -DMB, -DMA, -DOA, -DPA1, -DPB2, MICA, MICB, TAP1 
and TAP2. In the 5/6 HLA-matched pairs, the number of additional genes with allelic mismatches leading to a 
change at the amino acid level varied between three and seven (Table 2). Thus, the minimum number of genes 
with allelic disparities at four-digit resolution was four (pair 2468) and the maximum number was as high as eight 
Pair id
Clinical HLA typing
Imputation of HLA-A,-B,-
C,-DRB1,-DQA1,-DQB1 
and -DPB1 alleles
Genotyping of 5137 SNPs 
within 4 Mbp region of MHC
Total 
match
GvHD grading
HLA-A, -B, 
-DRB1 match
Mismatched 
HLA allele Mismatched HLA allele SNP mismatching in MHC Acute Chronic
2329 5/6 DRB1, DQB1 DRB1, DQB1, DQA1, DPB1 C4 to DPB1 11/14 na na
3205 5/6 A A, DPB1 A, DPB1 12/14 2 limited
4426 5/6 A A, DPB1 A, DPB1 12/14 0 extensive
4658 5/6 A A A 13/14 2 no
4754 5/6 B B C4 to HLA-E, telomeric to A 12/14 0 no
5366 5/6 B,C B,C, DPB1 B to C, DPB1 11/14 na na
1812 6/6 — DPB1 DPB1 13/14 0 na
3450 6/6 — DPB1 DPB1 13/14 0 no
4152 6/6 — DPB1 DPB1 13/14 0 no
5236 6/6 — DPB1 DPB1 13/14 0 no
2934 6/6 — — centromeric to DPB1 14/14 1 extensive
3446 6/6 — — centromeric to DPB1 14/14 1 limited
4706 6/6 — — centromeric to DPB1 14/14 0 limited
3803 6/6 — — telomeric to A 14/14 0 extensive
4205 6/6 — — non-HLA regions 14/14 3 limited
Table 1. HLA-mismatched haematopoietic stem cell transplantation (HSCT) pairs of study cohort 1 (N = 261 
sibling pairs) analysed by Immunochip single nucleotide polymorphism (SNP) array. Six pairs were known to 
have one mismatched allele at HLA-A, -B or -DRB1 gene based on clinical HLA typing prior to HSCT. Four 
additional pairs were revealed to be mismatched by HLA allele imputation based on SNP data. Disparity outside 
the classical HLA genes in five pairs was uncovered by comparison of 5137 SNPs in the major histocompatibility 
complex region (MHC). HLA = human leukocyte antigen; SNP = single nucleotide polymorphism; MHC = major 
histocompatibility complex; C4 = complement component 4; GvHD = graft versus host disease.
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(pair 5782). The matching status including all 34 MHC genes varied between 26/34 and 30/34. As expected, the 
number of mismatching was higher at the DNA level (six-digits), varying between five and nine (Fig. 2). All five 
pairs with mismatching at HLA-A had also mismatching at HLA-F, -G, -H, and/or -K located telomeric to HLA-A 
gene. Likewise, all pairs with HLA-B mismatching also had MICA mismatching and one pair also had MICB 
mismatching. In addition, some extra mismatching in these pairs occurred at other genes of the MHC class I. 
Interestingly, many pairs with allelic mismatching in the MHC class I also had allelic disparities in MHC class II 
genes centromeric to HLA-DQB1 gene. In this study cohort, no allelic HLA-DQA1 or -DQB1 mismatching was 
found, most probably due to the tight LD of the matched HLA-DRB1 alleles.
Consistent with the results of study cohort 1, not all of the 6/6 HLA-matched pairs were fully matched for the 
entire MHC. Pair 5672 had allelic mismatching at HLA-DPB1, -DOB and TAP2, and pair 6907 had mismatching 
at HLA-DPB1 together with HLA-DPA1 and -DOA (Table 2 and Fig. 2). In this cohort 8.9% (10/89) of the HSCT 
pairs were mismatched at least for one classical HLA allele.
MHC segment identity. The extent of the mismatched fragments in the 89 HSCT pairs was examined fur-
ther at the genomic sequence level (Fig. 1b). Again, the mismatched genomic regions covered larger segments 
around the particular gene with observed allelic HLA mismatching. Pairs 5426, 6245, and 6768 mismatched 
both at HLA-B and HLA-C showed mismatching at genomic segment starting from the telomeric side of HLA-C 
gene and ending centromeric to complement C4 gene in the MHC class III. The mismatched region in the pairs 
with allelic HLA-A disparity (pairs 2468, 5624, 5728, 5782, 6385) encompassed relatively long segments flanking 
the entire HLA-A gene. Two samples, 5559 and 7086, showed MHC fragment mismatching despite of having 
no mismatching at any of the 34 genes (Table 2 and Fig. 1b). The observed mismatching located centromeric 
to HLA-DPB2 gene in pair 5559 and telomeric to HLA-F gene in pair 7086. It is of note that approximately the 
same segments were also mismatched in some of the 5/6 HLA-matched pairs as well (5782, 6245, 6768, 7086). 
Altogether 4.9% (4/81) of the HLA matched HSCT pairs in study cohort 2 were found to have unexpected dispar-
ities in the MHC region. The remaining 77 fully HLA-matched HSCT sibling pairs were identical-by-state along 
the entire 4.5 Mbp MHC region, barring some sporadic single mismatched nucleotides (Supplementary Fig. S1).
Taking the two cohorts together, 7.7% (27/350) of the putative HSCT pairs were found to have mismatches in 
the MHC region of which 3.9% (13/336) were observed in fully HLA-A, -B, -C, -DRB1, -DQB1 matched pairs.
Figure 1. Genotype comparison map showing haematopoietic stem cell transplantation (HSCT) donor-
recipient pairs with large genomic fragments of mismatched single nucleotide polymorphisms (SNPs) in the 
major histocompatibility complex (MHC) segment. The mismatched HSCT pairs are shown in discovery 
order on the X-axis. Green depicts matched SNPs, yellow depicts mismatched and red indicates missing 
results or poor quality SNPs. Physical map of the MHC region with selected marker genes is shown on the left. 
The vertical axes in the similarity plot show the positions of SNP having a mismatch in at least one pair. (a) 
Identical-by-state status of 5137 SNPs covering the entire MHC gene complex by an Immunochip array in 15 
HSCT sibling pairs (study cohort 1). The Y-axis shows a segment of chromosome 6p21 encompassing positions 
29,002,062 bp (telomeric to HLA-F) to 33,496,714 bp (centromeric to HLA-DPB1). (b) Identical-by-state status 
of 12 HSCT pairs sequenced for the 4.5 Mbp MHC region (study cohort 2). The Y-axis shows a segment of 
chromosome 6p21 encompassing positions 29,000,825 bp (telomeric to HLA-F) to 33,477,140 bp (centromeric 
to HLA-DPB1).
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Recombination sites. The positions of the mismatched fragments were examined in both study cohorts 
(Supplementary Table S3). The boundaries of the mismatched segments were focused on restricted genomic 
regions and appeared to be non-random. The putative recombination sites in the MHC class I region clustered 
around position ~29.6 Mbp just telomeric to HLA-F gene and in the 1.0 Mbp segment around positions 30.0 Mbp 
and 31.0 Mbp, close to HLA-C gene, in the HLA-A mismatched pairs. The recombination sites between the MHC 
class I and class II clustered around position ~32.1 Mbp locating centromeric to complement C4 gene. In the 
MHC class II region, the recombination sites between HLA-DQB1 and -DPB1 genes clustered within a ~200-Kbp 
segment between positions 32.8 Mbp and 33.0 Mbp. All pairs with allelic mismatching at HLA-DPB1showed 
recombination in a surprisingly narrow segment of ~400 Kbp between positions 32.7 Mbp and 33.1 Mbp.
Effect of mismatching on risk of graft-versus-host disease. The number of subjects with clinical 
information was 255 for acute GvHD (no = 172, grade 1 or 2 = 58; grade 3 or 4 = 25) and 202 for chronic GvHD 
(no = 98; limited = 52; extensive = 52). Of these, MHC sequence mismatching occurred in 91 aGvHD cases and 
62 cGvHD cases, and out of mismatched aGvHD and cGvHD cases 85 and 56 were fully HLA-A, -B, -DRB1 
matched, respectively. We found a weak but consistent trend between the number of mismatched nucleotides 
within the MHC segment and the risk of both acute and chronic GvHD as estimated by odds ratio vs. mismatch 
threshold (Fig. 3a,b). The trend remained significant after excluding 5/6 HLA-matched pairs (Fig. 3c,d).
Pair id
Clinical HLA typing
NGS-HLA allele assignment of 
HLA-A,-B,-C,-DRB1,-DQA1, 
-DQB1 and -DPB1 genes
Determination of genomic 4.5 Mb 
sequence of the MHC region
Total 
match
GvHD grading
HLA-A,-B,-
DRB1 match
Mismatched 
HLA allele Mismatched HLA allele
HLA and non-HLA gene sequence 
mismatching Acute Chronic
2468 5/6 A A A, F, H, K 30/34 1 extensive
5426 5/6 B,C B, C, DPB1 B, C, MICA, TAP1, DPB1, DPB2 28/34 0 no
5624 5/6 A A A, H, TAP2, TAP1, DMA 29/34 na na
5728 5/6 A A A, F, H, K, L, E 28/34 0 limited
5782 5/6 A A, DPB1 A, F, H, K, DOB, TAP2, DPA1, DPB1 26/34 na na
6245 5/6 B,C B, C B, C, L, MICA, MICB 29/34 na na
6385 5/6 A A A, G, H, K, TAP2 29/34 na na
6768 5/6 B,C B, C B, C, E, MICA, DOB, TAP2, TAP1 27/34 1 extensive
5672 6/6 — DPB1 DPB1, DOB 32/34 na na
6907 6/6 — DPB1 DPB1, DPA1 32/34 na na
5559 6/6 — — centromeric and telomeric to DPB2 34/34 na na
7086 6/6 — — telomeric to F 34/34 0 limited
Table 2. HLA-mismatched haematopoietic stem cell transplantation (HSCT) pairs in study cohort 2 (N = 89 
sibling pairs) analysed by genomic sequencing of the major histocompatibility complex (MHC) region. Eight 
pairs were known to have one allelic mismatch at HLA-A, -B or -DRB1 gene based on clinical HLA typing 
prior to HSCT. Allelic mismatching at HLA-DPB1 was revealed in two pairs by next generation sequencing 
allele assignment. Two more pairs were uncovered to be mismatched by genomic sequence comparison of the 
entire MHC segment. Only those genes with mismatching at the amino acid level are shown. + . HLA = human 
leukocyte antigen; MHC = major histocompatibility complex; MICA = MHC class I chain-related gene A; 
MICB = MHC class I chain-related gene B; TAP1 = transporter 1, ATP binding cassette subfamily B member; 
TAP2 = transporter 2, ATP binding cassette subfamily B member; GvHD = graft versus host disease.
Figure 2. Allelic mismatching in cohort 2 of 34 genes located in the major histocompatibility complex region. 
The genes are listed from the telomeric end (HLA-F) to the centromeric end (HLA-DPB2). The classical HLA-A, 
-B, -C, -DRB1 and -DQB1 genes are highlighted. The eight uppermost haematopoietic stem cell transplantation 
pairs are 5/6 HLA-matched, and pairs 5672 and 6907 are 6/6 HLA-matched siblings. Alleles of the 34 genes are 
assigned based on exon sequence analysis at six-digit resolution level. Allelic mismatching that results in amino 
acid change is depicted in grey. Mismatching that remains at the DNA level (silent mutations) is marked with 
stripes.
www.nature.com/scientificreports/
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Discussion
In the present study, we used SNP genotyping and genomic sequencing to investigate the matching of the entire 
MHC region in 350 fully or partially HLA-A, -B and -DRB1 matched sibling donor-recipient HSCT pairs. The 
basic questions addressed in the study were: how frequently do HLA-A, -B, -DRB1 matched pairs have mis-
matching in the MHC region, how large genomic fragments do them cover and does the level of mismatching 
correlate with the occurrence of graft-versus-host disease? Altogether, 7.7% of all HSCT pairs and 3.9% of those 
pairs without a prior mismatch at HLA-A, -B or -DRB1 were found to have genomic differences in the MHC 
segment. Hence, hidden mismatching at HLA and non-HLA regions in the MHC were uncovered not only in 5/6 
HLA-matched pairs but also in 6/6 HLA-matched pairs. The mismatched genomic fragments were larger than 
just a single HLA gene with allelic mismatch, sometimes covering many flanking genes. It is of note that our mate-
rial was retrospective and HLA typing and matching were done as recommended during the years 1993–2011. 
Currently, the technological advance, in particular, has led to typing of a wider HLA profile in some laboratories. 
Importantly, despite of the limited sample size in this study, the number of mismatched SNPs showed a positive 
association with the risks of acute and chronic GvHD even after excluding the cases with known prior mismatch-
ing at HLA-A, -B, or DRB1. This result supports the primary role of matching the HLA segment in HSCT.
We determined the allelic variation in 34 genes located in the MHC and found that some pairs were only 
matched for 26 of these genes. Allelic mismatching at HLA-A usually resulted in mismatching at the non-classical 
HLA-F and -G as well as at pseudogenes HLA-H and -K. Likewise, mismatching at HLA-B encompassed mis-
matching at HLA-C and MICA and in one sample also at MICB. Allelic mismatching at HLA-DPB1 gene were rel-
atively common, independently or together with mismatching elsewhere and, interestingly, usually also included 
TAP1 or TAP2 genes. In addition, we found a few cases with isolated allelic mismatching at HLA-DOB, TAP1, 
TAP2, HLA-DMA and HLA-DOA genes, without detectable mismatching at other MHC class II genes, indi-
cating either highly-similar but different haplotypes or intra-MHC recombination. It seems that the functional 
Figure 3. Trend toward higher risk for graft-versus-host disease (GvHD) along increasing number of 
nucleotide mismatches between haematopoietic stem cell transplantation (HSCT) donor-recipient pairs in 
study cohort 1. The donor-recipient pairs are divided into low and high mismatch groups according to the 
total number of MHC region genotype differences between each pair. Similarly, each pair is also assigned into 
either aGvHD positive or negative group according to the recipient’s clinical GvHD gradus. The mismatch 
and GvHD categorized data are then arranged into a contingency table to calculate the odds ratio (OR). The 
mismatch threshold value, defined as the natural logarithm of the number of total SNP genotype differences per 
each HSCT sibling pair, is varied from 0 to 6 and the corresponding odds ratio is calculated for each threshold 
value. Thus, each data point represents an odds ratio at a particular threshold value. Moreover, two alternate 
definitions for the GvHD negative status are used: grade 0 (no) or grades 0–2 (no/limited) in acute GvHD, 
and no GvHD or no/limited in the chronic GvHD. The plots show the odds ratios (y-axis) against the varying 
mismatch threshold values (x-axis). (a) Acute (n = 91) and (b) chronic (n = 62) GvHD for cohort 1, and (c) 
acute (n = 85) and (d) chronic (n = 56) GvHD for fully HLA A-B-DRB1 matched cohort 1 pairs. Pairs with 
zero MHC mismatches are omitted. Linear regression lines are shown for both GvHD negative groups by their 
corresponding colours. Correlation is calculated by Kendall’s rank correlation. aGvHD, acute graft-versus-host 
disease; cGvHD chronic graft-versus-host disease; OR, odds ratio.
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consequences of a single allelic HLA mismatch can be wider than assumed. If all haplotypes in a family are not 
known, genotyping of the seven most important classical HLA genes in every sibling pair setting should be per-
formed to ensure the HLA identity between a transplant pair. This action would only ensure the HLA identity 
but not the haplotype identity, as mismatches were also observed in large areas of the intervening sequence. To 
ascertain the haplotype identity a high-density SNP panel covering the entire MHC would be needed.
There is evidence that variations in HLA-DPB1, -G, -E and MICA genes are associated with immunological 
diseases, including also reports on graft-versus-host diseases5,22–26 and graft rejection27. The role of allelic mis-
matching at HLA-DPB1 in HSCT appears to be complex as it is related to expression level23 and so called per-
missive and non-permissive mismatch groups22,27,28. It is also known that even a single allelic mismatch at HLA 
can induce an alloimmune response29,30, including graft-versus-leukemia effect, a favourable phenomenon that 
reduces the risk of relapse31,32. Hence, our finding that the number of mismatched nucleotides correlates with the 
GvHD risk fits well to these findings.
The MHC region is known to have relatively conserved genomic blocks of a few to hundreds of thousands of 
kilobases in length. These blocks are flanked by recombination sites or hot spots33,34 resulting in the sharing of 
these segments by many unrelated individuals or different haplotypes. The borders of the mismatched segments 
observed in 27 pairs of this study were in agreement with the published recombination sites within the MHC class 
I, II and III regions15,16. Sometimes MHC blocks may span several megabases of DNA, covering almost the entire 
MHC fragment and are referred to as ancestral or conserved extended MHC haplotypes (AH or CEH)10–13. These 
long and fixed haplotypes are remarkably conserved, having a high level of allele identity across the MHC. For 
example, the most frequent North European HLA haplotype, 8.1 AH (HLA-A1-B8-DR3), is 92–98% congruent, 
but some polymorphisms are found telomeric to HLA-A and centromeric to HLA-DQB135. The level of congru-
ence can vary greatly depending on the haplotype group, especially if they are not AHs14. It is therefore possible 
that there are many different copies of the same haplotype in a family and that fully HLA-matched siblings are 
not haplotype identical36. This may explain SNP mismatching in the non-HLA MHC regions of the seven 6/6 
HLA-matched pairs although meiotic recombination cannot be excluded.
As no parents or children were available for HLA typing due to the clinical practice in Finland, the sibling 
pairs could be only classified identical-by-state but not by-descent. It is therefore not possible to know whether 
mismatching between 5/6 HLA-matched siblings was due to meiotic recombination or because the siblings had 
inherited different but very similar haplotypes with only one allelic difference at HLA. For example, two similar 
haplotypes that are very frequent in the Finnish population, A*02:01-C*07:02-B*07:2-DRB1*15:01-DQB1*06:02 
and A*03:01-C*07:02-B*07:2-DRB1*15:01-DQB1*06:02, can readily occur within a single family. Alternatively, 
parental chromosomes may by chance carry the same HLA alleles, but in completely different haplotypes, i.e., 
siblings have inherited different chromosomes from their parents. This may be the case in pair 4205, which was 
identical at the classical HLA-A, -B, and -DRB1 genes, but large segments with mismatched SNPs were observed 
in the sequence between them. The frequencies of the putative haplotypes that can be formed from the pair’s HLA 
combinations (HLA-A*02:01, 11:01; C*03:03, 03:03; B*15:01, 55:01; DRB1*13:01, 14:01; DQB1*05:03, 06:03) 
vary between 0.014 and 0.0003 in the Finnish population according to our unpublished results, which ranks 
10th–412th in haplotype frequency.
To our knowledge, this type of study in which MHC sequences between sibling pairs are scrutinised in detail 
has not been performed before. The discovery of hidden mismatches within the MHC that can encompass many 
genes, even in fully HLA-matched HSCT pairs, could encourage HLA laboratories to screen the MHC region 
more thoroughly with new DNA techniques in particular as there is a trend towards higher risk of GvHD along 
the number of mismatched nucleotides. The present study also provides useful information on the extent of MHC 
variation, which is important as haploidentical HSCTs are now becoming more into practice.
Material and Methods
Study cohorts and DNA extraction. Two different study cohorts were examined. Study cohort 1 was com-
posed of 261 HSCT sibling pairs and cohort 2 of 89 possible HSCT sibling pairs. The actual transplantations of the 
cohorts were done between the years 1993 and 2011. Genomic DNA from the white blood cell fraction of whole 
blood was extracted with QiaAmp Blood minikit columns (Qiagen GmbH, Germany). This study was carried out 
in accordance with the recommendations of the Ethical Committee of Helsinki University Hospital with written 
informed consent from living subjects. The authority operating under the Ministry of Social Affairs and Health, 
Valvira, approved the study for deceased subjects. Demographic details and clinical outcomes including GvHD 
grading of HSCT pairs of cohort 1 are described in Supplementary Table S4 and in our previous studies37,38.
Clinical HLA typing. Clinical HLA typing was performed at the HLA Laboratory of the Finnish Red Cross 
Blood Service using procedures accredited by the European Federation for Immunogenetics (EFI). All patients 
and donors of cohort 1, whose HSCT were done between the years 1993–2006, were typed for HLA-A, -B and 
-DRB1 either by the serological method (Lymphotype HLA-AB and Lymphotype HLA-DR, Bio-Rad Medical 
Diagnostics, Dreieich, Germany) or by PCR-based typing methods at two-digit resolution level (a LIPA reverse 
dot blot kit, Innogenetics Group, Gent, Belgium or Pel Freez HLA-SSP kits, Dynal Biotech LLC, Oslo, Norway). 
Depending on a given time period HLA-C and/or -DQB1 genes were also genotyped at four-digit resolution level 
in the pairs with antigen mismatching at any of HLA-A, -B or -DRB1 (5/6 HLA-matched pairs) conforming to the 
requirements given by EFI effective at the time.
Study cohort 2, whose HSCT were done between the years 2006–2011, was HLA-A, -B, -C, -DQB1 and -DRB1 
genotyped at two-digit resolution level by rSSO-Luminex technology (Labtype, One Lambda, Inc., CA, USA) and 
PCR-SSP (Micro SSP™ Generic HLA Class I/II DNA Typing Trays, One Lambda, Inc.; Olerup SSP® genotyping, 
Olerup SSP AB, Stockholm, Sweden). The 5/6 HLA-matched pairs were retyped by sequence-based typing at 
four-digit resolution level (AlleleSEQR PCR/Sequencing kits, Atria Genetics, Hayward, CA, USA) using ABI 
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3130xl genetic analyzer (Applied Biosystems, Thermo Fisher Scientific, MA, USA). The results were analysed with 
Assign 3.5+ software (Conexio Genomics Pty Ltd, Fremantle, Australia.
Depending on the recommendations by EFI at any given time period, the clinical HLA typing did not result in 
the homogeneous set of HLA genes typed and/or the assignation of the alleles at the same resolution. To simplify 
the analyses, antigenic matching at HLA-A, -B, -C, -DRB1 and -DQB1 was set as the starting point.
Immunochip array. Study cohort 1 was genotyped at the Institute for Molecular Medicine Finland, 
University of Helsinki, by using Immunochip array (Illumina, Inc., CA, USA). The Immunochip included 8215 
SNPs within the DNA segment from the telomeric side of HLA-F gene to the centromeric side of HLA-DPB2 gene 
at positions 29–33.5 Mbp (Genome Reference Consortium human [GRCh]37/hg19). The initial quality control 
identified samples with discordant sex information, duplicate samples, call rate <97%, and heterozygosity excess 
<−0.3 (not X chromosome) or >0.2, and >0.1 for the X chromosome. The data were quality-filtered according 
to Anderson et al.39. After quality controls, 5137 SNPs were included in the study.
The alleles of the classical HLA-A, -B, -C, -DRB1, -DQA1, -DQB1 and -DPB1 genes were imputed at four-digit 
resolution level using the software HLA*IMP:0240 (The Oxford HLA Imputation Framework, UK). Missing data 
threshold was set to 0.20. SNPs were aligned and genotypes phased against HapMap (CEU) reference panel 
(hapmap3_r27_b36_fwd.consensus.qc.poly.chr6_ceu.). The absolute posterior probability scores Q2 for each 
imputed genotype were produced by using threshold T = 0.00.
Genomic sequencing. Genomic sequencing of the full MHC region in samples of cohort 2 was performed 
at the McGill Genome Centre, McGill University, Montreal, Canada, using Roche SeqCap EZ Human MHC 
Design capture, which captures approximately 95% of the MHC region41. Sequencing was performed with an 
Illumina HiSeq. 2000, yielding 100 bp paired-end reads and a median on-target coverage of 27.5 × per sample. 
The generated reads were aligned to the GRCH37/hg19 reference genome. Base quality score recalibration and 
SNP and INDEL discovery were performed using GATK v.3.6-0 VariantRecalibrator and ApplyRecalibration 
tools with the default settings. The used ts_filter_level setting was 99.042–44. The data were filtered using the hard 
cutoffs of the total depth of coverage per sample >7 and genomic quality >1945.
For HLA typing, the fastq read data were quality checked using FastQC46, and adapters were trimmed using 
Cutadapt47. The Omixon Explore program version 1.2.0 (Omixon, Budapest, Hungary) was used for allele assign-
ment of 30 genes at six-digit resolution level comprising both classical HLA genes, non-classical HLA genes and 
pseudogenes in the MHC region using the IMGT/HLA database’s HLA nomenclature release 3.25.0: HLA-F, 
HLA-V, HLA-G, HLA-H, HLA-K, HLA-A, HLA-J, HLA-L, HLA-E, HLA-C, HLA-B, HLA-DRA, HLA-DRB1-9, 
HLA-DQA1, HLA-DQB1, HLA-DOB, HLA-DMB, HLA-DMA, HLA-DOA, HLA-DPA1, HLA-DPB1, 
HLA-DPB2. In addition, the alleles of the two MHC class I chain-related genes MICA and MICB as well as two 
ATP binding cassette transporter genes, TAP1 and TAP2, were assigned.
MHC mismatch analysis. The genotypes of each HSCT sibling donor-recipient pair were compared 
position-by-position over the segment 29–33.5 Mbp of chromosome 6p21.3 by classifying each position into 
to one of three categories: the diploid genotype in a given position between pairs was identical, not identical or 
missing. Genotype positions with missing calls of over 5% were removed before the comparison. For study cohort 
1, which was genotyped with Immunochip, the data were first transformed into tped format using plink v.10748 
and then managed with R v.3.3.349. For study cohort 2, the VCF data file was read into R using the seqminer 
library v.5.750 and then managed similarly to study cohort 1. Positions that were identical over all of the included 
pairs were removed before analysis and plotting. The final pair comparison result matrix was plotted with the R 
library lattice v.0.20–35 function levelplot51. Recombination segments were identified based on visual inspection 
of pairwise comparison of genotype similarity plot.
Statistical analysis. Study cohort 1 was used for analysing the association of GvHD clinical status with the 
extent of pairwise MHC mismatching. The analysis was performed by first counting the natural logarithm of total 
number of MHC mismatches in each HSCT sibling donor-recipient pair and then dividing the pairs into ‘high’ and 
‘low’ mismatch groups. Due to the log transform, pairs with zero mismatches were omitted from analysis. Similarly, 
each pair was assigned into either a GvHD positive or negative group according to the recipient’s clinical GvHD 
gradus. The mismatch and GvHD categorized data were arranged into a contingency table to calculate the odds 
ratio (OR). The cutoff in defining the ‘high’ and ‘low’ mismatch pairs was varied from 0 to 6. The odds ratio was 
then calculated over the varying cutoff values and correlation between the cutoff and odds ratio was calculated with 
Kendall’s rank correlation. The correlation p-value was calculated with the R function cor.test. The linear relationship 
was visualized using regression line with its 95% confidence intervals on the odds ratio vs. cutoff plots. Furthermore, 
to estimate the robustness of the correlation at different definitions of GvHD positive and GvHD negative groups, 
either grade 0 subjects or grades 0–2 subjects were included in the negative acute GvHD group and either no GvHD 
or no/limited GvHD subjects were included in the negative chronic GvHD group. To estimate the possible effect of 
HLA-A,-B,-DRB1 mismatching that was known before the HSCT, the mismatched pairs were removed and the same 
analysis procedure was carried out for only the fully matched pairs. The analysis was done with R v.3.3.349.
Data availability statement. Data reported in this study is not available due to the limitations set by 
Ethical committee.
Ethical approval and informed consent. All experiments were carried out in accordance with relevant guide-
lines and regulations defined in the Finnish legislation. The Ethical Committee of the Helsinki University Hospital and 
Valvira, the authority operating under the Ministry of Social Affairs and Health, have approved the study.
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